Search Results 1121-1130 of 13332 for monoclonal antibody

  1. Prevalence Of MIC A Antibodies In T1D - Mayo Clinic

    About this study. The purpose of this study is to evaluate the prevalence of MIC A antibodies in adult participants with T1D ...

  2. A Study Of SC-006 In Subjects With Advanced Cancer - Mayo Clinic

    ... monoclonal antibodies, antibody drug conjugates, radioimmunoconjugates, or T-cell orother cell-based therapies: 4 weeks (2 weeks permissible before the ...

  3. Brandon Wilbanks: Finding DNA Molecules That Can Transport Drugs Inside Cells - Student Research - Mayo Clinic College of Medicine & Science

    ... antibodies to cells ultimately may expand the potential targets for antibody drugs. Confocal microscopy image ...

  4. A Trial Of ZL-1201 In Subjects With Advanced Cancer - Mayo Clinic

    About this study. First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer. Participation eligibility.

  5. Stopping Versus Continuation Of Long-term Mepolizumab In Severe Eosinophilic Asthma Patients - Mayo Clinic

    Other Monoclonal Antibodies: Subjects who have received any monoclonal antibody (other than XOLAIR®) to treat inflammatory disease within 5 half-lives of Visit ...

  6. A Dose Escalation And Confirmation Study Of PT-112 In Advanced Solid Tumors In Combination With Avelumab - Mayo Clinic

    ... antibody, avelumab, in selected advanced solid tumors. ... Known prior severe hypersensitivity reaction to monoclonal antibodies (grade ≥3 by NCI CTCAE v4.

  7. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

    ... monoclonal antibody (bevacizumab, ramucirumab, or aflibercept), and an anti-PD-1 monoclonal antibody (nivolumab or pembrolizumab) if tumor has deficient ...

  8. Coronavirus Disease 2019 (Covid 19 Clinical Trials - Mayo Clinic Research

    ... antibody detectable targets on cancer cells (cancer vaccines or antibody ... Monoclonal Antibodies To Treat Hospitalized Patients With COVID-19 Rochester, MN.

  9. Testing The Addition Of An Anti-cancer Drug, ASTX727, To Chemotherapy (Paclitaxel) And Immunotherapy (Pembrolizumab) For Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    PD-1/PD-L1 monoclonal antibodies in any disease setting are eligible. - For ... monoclonal antibody agent, ASTX727 is a hypomethylating agent, and ...

  10. Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, And Cyclophosphamide In Treating Patients With Triple Negative Breast Cancer - Mayo Clinic

    ... (monoclonal antibody, small molecule pathway inhibitor). Treatment with systemic corticosteroid or immune-modulators ≤ 7 days prior to randomization ...